Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells

Biochemical and Biophysical Research Communications

Volumn 387, Issue 2, 2009, Pages 239-244

  Zhao, Meng ^a   He, Hong wei ^a   Sun, Huan xing ^a   Ren, Kai huan ^a   Shao, Rong guang ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Epiregulin; EREG; Microarray; Multi targeted therapy; N Ras; RNAi

Indexed keywords

CYCLIN D1; EPIREGULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EREG GENE; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; EPIDERMAL GROWTH FACTOR; G0 PHASE; G1 PHASE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING;

EID: 67949120217     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.128     Document Type: Article

References (34)

1. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3 6 (2003) 459-465
2. Rajalingam K., Schreck R., Rapp U.R., and Albert S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773 8 (2007) 1177-1195
3. Tabor E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J. Med. Virol. 42 4 (1994) 357-365
4. Dan L., Qi-Fu L., Gove C., Naomov N.V., Jian-Jia S., and Williams R. Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas. World J. Gastroenterol. 4 2 (1998) 97-99
5. Richards C.A., Short S.A., Thorgeirsson S.S., and Huber B.E. Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis. Cancer Res. 50 5 (1990) 1521-1527
6. Greten T.F., Korangy F., Manns M.P., and Malek N.P. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer 100 1 (2009) 19-23
7. Höpfner M., Schuppan D., and Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J. Gastroenterol. 14 1 (2008) 1-14
8. Shi X.H., Liang Z.Y., Ren X.Y., and Liu T.H. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther. 16 3 (2009) 227-236 Epub 2008 October 24
9. H.X. Sun, H.W. He, S.H. Zhang, T.G. Liu, K.H. Ren, Q.Y. He et al., Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition, Cancer Gene Ther. (2009) [Epub ahead of print].
10. Janmaat M.L., Rodriguez J.A., Gallegos-Ruiz M., Kruyt F.A., and Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int. J. Cancer 118 1 (2006) 209-214
11. Shao R.G. Small interfering RNA mediated multi-targeted therapy of cancer. Acta Pharm. Sin. 44 3 (2009) 1-6
12. Yin J.Q., Gao J., Shao R., Tian W.N., Wang J., and Wan Y. SiRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J. Exp. Ther. Oncol. 3 (2003) 194-204
13. Hong J., Zhao Y., and Huang W. Blocking c-myc and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma. Biochem. Biophys. Res. Commun. 348 (2006) 600-605
14. Kunze D., Wuttig D., Fuessel S., Kraemer K., Kotzsch M., Meye A., et al. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-XL) in bladder cancer cells. Anticancer Res. 28 (2008) 2259-2263
15. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., et al. Normalization for cDNA microarray data: a robust composite method addressing single, multiple slide systematic variation. Nucleic Acids Res. 30 (2002) e15
16. Liu T.G., Yin J.Q., Shang B.Y., Min Z., He H.W., Jiang J.M., et al. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther. 11 11 (2004) 748-756
17. Toyoda H., Komurasaki T., Uchida D., Takayama Y., Isobe T., Okuyama T., et al. Epiregulin: a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 270 (1995) 7495-7500
18. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 7 (2007) 2557-2576
19. Patrick A., and Liam J.T. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J. Gastroenterol. 14 11 (2008) 1670-1681
20. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
21. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24 (2006) 1-8
22. Toyoda H., Komurasaki T., Uchida D., and Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem. J. 326 Pt. 1 (1997) 69-75
23. Zhu Z., Kleeff J., Friess H., Wang L., Zimmermann A., Yarden Y., et al. Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem. Biophys. Res. Commun. 273 3 (2000) 1019-1024
24. Wang X., Colby J.K., Rengel R.C., Fischer S.M., Clinton S.K., and Klein R.D. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes. Mol. Carcinog. 48 1 (2009) 1-13
25. Ben-Ami I., Armon L., Freimann S., Strassburger D., Ron-El R., and Amsterdam A. EGF-like growth factors as LH mediators in the human corpus luteum. Hum. Reprod. 24 1 (2009) 176-184
26. Hu K., Li S.L., Gan Y.H., Wang C.Y., and Yu G.Y. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. Oral Oncol. 45 2 (2009) 156-163
27. Meloche S., and Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 22 (2007) 3227-3239
28. Knudsen E.S., Buckmaster C., Chen T.T., Feramisco J.R., and Wang J.Y. Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev. 12 15 (1998) 2278-2292
29. Chen X.L., Ren K.H., He H.W., and Shao R.G. Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1 arrest and apoptosis. Cancer Biol. Ther. 7 7 (2008) 1073-1078
30. Zhou L., Jiang Y., Tan A., Greenlee A.R., Shen Y., Liu L., et al. Silencing of N-Ras gene expression using shRNA decreases transformation efficiency and tumor growth in transformed cells induced by anti-BPDE. Toxicol. Sci. 5 2 (2008) 86-94
31. Komurasaki T., Toyoda H., Uchida D., and Morimoto S. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 15 (1997) 2841-2848
32. Shelly M., Pinkas-Kramarski R., Guarino B.C., Waterman H., Wang L.M., Lyass L., et al. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J. Biol. Chem. 273 (1998) 10496-10505
33. Höpfner M., Sutter A.P., Gerst B., Zeitz M., and Scherübl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br. J. Cancer 89 (2003) 1766-1775
34. Höpfner M., Sutter A.P., Huether A., Schuppan D., Zeitz M., and Scherübl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol. 41 6 (2004) 1008-1016